Drug Trial Radar · NCT07834138
Facial Skin Microbiome in Patients With Moderate-to-Severe Acne Vulgaris Treated With Isotretinoin
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 13, 2026
Primary completion
Feb 7, 2027
Study completion Mar 7, 2027
Sponsor
- Lead sponsor
- Can Tho University of Medicine and PharmacyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Acne vulgaris is associated with changes in the facial skin microbiome, but longitudinal microbiome changes during isotretinoin therapy remain incompletely understood. This prospective observational cohort study aims to characterize the facial skin microbiome in patients with moderate-to-severe acne vulgaris before and during isotretinoin treatment and to compare microbiome profiles with healthy individuals. Participants with moderate-to-severe acne vulgaris receiving standard-of-care oral isotretinoin will be followed prospectively. Facial skin swab samples will be collected before treatment and at scheduled follow-up visits during therapy. Healthy volunteers without acne will provide a single facial skin swab for comparison. Bacterial communities will be analyzed using 16S rRNA gene sequencing, and clinical severity will be assessed using validated acne severity scores and lesion counts. The study will evaluate changes in microbial diversity, bacterial composition, and the relative abundance of acne-associated microorganisms during isotretinoin treatment. Associations between microbiome changes and clinical improvement will also be explored. Results are expected to improve understanding of the role of the skin microbiome in acne and provide evidence for future microbiome-based therapeutic strategies.
Conditions
- Acne Vulgaris
Interventions
ISOtretinoin 10 MGDrug
Oral isotretinoin administered as part of routine clinical care according to institutional treatment protocols. The study does not assign or modify isotretinoin treatment; investigators prospectively
Primary outcomes
What the sponsor says the trial is designed to measure.
- Shannon-Wiener Diversity Index of the Facial Skin Microbiome at BaselineTime frame: At baseline, before isotretinoin treatment in the acne cohort
- Change in Shannon-Wiener Diversity Index of the Facial Skin Microbiome During Isotretinoin TreatmentTime frame: Baseline to Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Can Tho University of Medicine and Pharmacy Hospital
Can Tho, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.